Hydralazine-Induced Relapsing Polychondritis-Like Syndrome: Report of a Case with Severe Chronic Laryngeal Complications

References

• Arkin C. R., Masi A. T. Relapsing polychondritis: Review of current status and case report. Sem in Arthritis Rheum 1975; 5: 41
   PubMedGoogle Scholar
• Batchelor J. R., Welsh K. I., Mansilla Tinoco R., Dollery C. T., Hughes G. R. V., Bernstein R., Naish P. F., Aber G. M., Bing R. F., Russel G. I. Hydralazine-induced systemic lupus erythematosus: Influence of HLA-DR and sex on suspectibility. Lancet 1980; 8178: 1107
   Google Scholar
• Boman G. Hydralazine-induced lupus, reported to the Swedish Adverse Drug Reaction Committee. Pharmacological and clinical aspects of hydralazine in today's treatment of hypertension. Symposium 1977, CIBA 147, 1978
   Google Scholar
• Celada A., Barras C., Benzonana G., Jeannet M. Increased frequency of HLA-Drw3 in systemic lupus erythematosus. New Eng J Med 1979; 301: 1398
   PubMedGoogle Scholar
• Charpentier I. L., Chomette G., Baubion D., Leclerc J. P., Bletry O., Godeau P., Auriol M. La polychondrite chronique atrophiante. Semaine Hôp Paris 1981; 57: 877
   PubMedGoogle Scholar
• Chisholm J. C. Acute low-dose hydralazine induced lupus syndrome (HILS). J Nat Med Ass 1981; 73: 258
   Google Scholar
• Clayton R. N., Hoffenberg R. Relapsing polychondritis: an autoimmune disease?. Br Med J 1978; ii: 999
   Google Scholar
• Cohnen G. Lupus erythematodes durch Medikamente. Med Monatsschr Pharm 1981; 4: 45
   PubMedGoogle Scholar
• Damiani J. M., Levine H. L. Relapsing polychondritis. Report often cases. Laryngoscope 1979; 89: 929
   PubMed Web of Science ®Google Scholar
• Diamant H., Schiratzki H. Chronic fibrosis of the subglottic space and possibly the paranasal sinuses and tympanic cavities. Laryngoscope 1969; 79: 355
   PubMedGoogle Scholar
• Dolan D. J., Lemmon G. B., Teitelbaum S. L. Relapsing polychondritis. Am J Med 1966; 41: 285
   PubMed Web of Science ®Google Scholar
• Drayer D. E., Reidenberg M. M. Clinical consequences of polymorphic acetylation of basic drugs. Clin Pharmacol Ther 1977; 22: 251
   PubMed Web of Science ®Google Scholar
• Ebringer R., Rook G., Swana G. T., Bottauo G. F., Doniach D. Autoantibodies to cartilage and type II. collagen in relapsing polychondritis and other rheumatic diseases. Ann Rheum Dis 1981; 40: 473
   PubMed Web of Science ®Google Scholar
• Evans D. A. P., Manley K. A., McKusick V. A. Genetic control of isoniazid metabolism in man. Brit Med J 1960; ii: 485
   Google Scholar
• Evans D. A. P., White T. A. Human acetylation polymorphism. J Lab Clin Med 1964; 63: 394
   PubMed Web of Science ®Google Scholar
• Foidart J. M., Abe S., Martin G. R., Zizic T. M., Barnett E. V., Lawley T. J., Katz S. I. Antibodies to Type II collagen in relapsing polychondritis. N Eng J Med 1978; 299: 1203
   PubMed Web of Science ®Google Scholar
• Gange R. W. Relapsing polychondritis. Report of two cases with an immunopathological review. Clin Exp Derm 1976; 1: 261
   PubMed Web of Science ®Google Scholar
• Goldwater C. Relapsing polychondritis. Acta Rheum Scand 1963; 9: 245
   PubMedGoogle Scholar
• Hanngren Å, Borgå H O., Sjökvist F. Inactivation of isoniazid (INH) in Swedish tuberculous patients before and during treatment with para-aminosalicylic acid (PAS). Scand J Resp Dis 1970; 51: 61
   PubMedGoogle Scholar
• Herman J. H., Dennis M. C. Immunopathologic studies in relapsing polychondritis. J Clin Invest 1973; 52: 549
   PubMed Web of Science ®Google Scholar
• Hughes G. R. V. Connective Tissue Diseases2nd edn. 1981; 178
   Google Scholar
• Jaksch-Wartenhorst R. Polychondropathia. Wien Arch Inn Med 1923; 6: 93
   Google Scholar
• Karlsson E., Molin J. Polymorphic acetylation of procainamide in healthy subjects. Acta Med Scand 1975; 197: 299
   PubMedGoogle Scholar
• Kaye R. L., Sones D. A. Relapsing polychondritis. Ann Intern Med 1964; 60: 653
   PubMed Web of Science ®Google Scholar
• Kilman W. J. Narrowing of the airway in relapsing polychondritis. Radiology 1978; 126: 373
   PubMed Web of Science ®Google Scholar
• Kindblom L. G., Dalén P., Edmar G., Kjellbo H. Relapsing polychondritis. A clinical, pathologic-anatomic and histochemical study of 2 cases. Acta Path Microbiol Scand 1977; 85: 656
   Google Scholar
• Liot F., Lemaigre D., Dessanges J. F., Leroy M. Polychondrite chronique atrophiante avec atteinte respiratoire prédominante. Ann Méd Interne 1980; 131: 519
   PubMedGoogle Scholar
• Lunde P. K. M., Frislid K., Hansteen V. Disease and acetylation polymorphism. Clin Pharmaco-kinetics 1977; 2: 182
   PubMed Web of Science ®Google Scholar
• McAdam L. P., O'Hanlan M. A., Bluestone R., Pearson C. M. Relapsing polychondritis. Medicine 1976; 55: 193
   PubMed Web of Science ®Google Scholar
• McCaffrey T. V., McDonald T. J., McCaffrey L. A. Head and neck manifestations of relapsing polychondritis. Review of 29 cases. Otolaryngol 1978; 86: 473
   Google Scholar
• Moloney J. R. Relapsing polychondritis—its otolaryngological manifestations. J Laryngol Otol 1978; 92: 9
   PubMedGoogle Scholar
• Pearson C. M., Kline H. M., Newcomer V. D. Relapsing polychondritis. J Med 1960; 263: 52
   Google Scholar
• Perry H. M., Schroeder H. A. Syndrome simulating collagen disease caused by hydralazine (Apreso-line). J.A.M.A. 1954; 154: 670
   PubMed Web of Science ®Google Scholar
• Perry H. M. Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis. Am J Med 1973; 54: 58
   PubMed Web of Science ®Google Scholar
• Rajapakse D. A., Bywaters E. G. L. Cell-mediated immunity to cartilage proteoglycan in relapsing polychondritis. Clin Exp Immunol 1974; 16: 497
   PubMed Web of Science ®Google Scholar
• Reinertsen J. L., Klippel J. H., Hohnson A. H., Steinberg A. D., Decker J. L., Mann D. L. B-Lymphocyte alloantigens associated with systemic lupus erythematosus. N Eng J Med 1978; 299: 515
   PubMed Web of Science ®Google Scholar
• Rosen T., Carr P O. Relapsing polychondritis. Cutis 1981; 28: 274
   PubMedGoogle Scholar
• Schröder H. Simplified method for determining acetylator phenotype. Brit Med J 1972; iii: 506
   Google Scholar
• Strandberg I., Boman G., Hassler L., Sjöqvist F. Acetylator phenotype in patients with hydrala-zine-induced lupoid syndrome. Acta Med Scand 1976; 200: 367
   PubMedGoogle Scholar
• Thould A. K., Stanfeld A. G., Balme H. W. Chronic atrofic perichondritis. Ann Rheum Dis 1965; 24: 563
   PubMed Web of Science ®Google Scholar
• Uetrecht J. P., Woosley R. L. Acetylator phenotype and lupus erythematosus. Clin Pharmacokinet 1981; 6: 118
   PubMed Web of Science ®Google Scholar
• Valenzuela R., Coopemder P. A., Gogate P., Deodhar S. D., Bergfeld W. F. Relapsing polychondritis. Human Path 1980; 11: 19
   PubMed Web of Science ®Google Scholar
• Verity M. A., Larson W. M., Madden S. C. Relapsing polychondritis. Am J Path 1963; 42: 251
   PubMedGoogle Scholar
• Weinstein A. Drug-induced systemic lupus erythematosus. Prog Clin Immunol 1980; 4: 1
   PubMedGoogle Scholar
• Ödkvist L. Relapsing polychondritis. Acta Otolaryngol (Stockh) 1970; 70: 448
   PubMed Web of Science ®Google Scholar